Diagnostic performance of glomerular PLA2R and THSD7A antibodies in biopsy confirmed primary membranous nephropathy in South Africans

Bingileki F Lwezaula 1,2,3, Oluwatoyin I Ameh 4, Udeme E Ekrikpo 5, Francois CJ Botha 6,7, Ugochi S Okpechi-Samuel 8, Nicola Wearne 1,2, Pierre Ronco 9, Aminu K Bello 10 and Ikechi G. Okpechi 1,2,10*

Abstract

Background: Serum and tissue-based tests using phospholipase A2 receptor 1 (PLA2R) and thrombospondin type-1 domain containing 7A (THSD7A) are established immune biomarkers for the diagnosis of primary membranous nephropathy (PMN). This study assessed the diagnostic performance of these biomarkers in the diagnosis of PMN in South Africans.

Methods: This was a cross-sectional analysis from a single centre in Cape Town, South Africa. Relevant biodata was collected from all patients. Histology, including slides for PLA2R and THSD7A were processed and assessed by typical microscopic and immunohistochemical features. Biopsy tissues of patients with membranous lupus nephritis (LN-V) and diabetic nephropathy (DN) were used as controls. The diagnostic accuracy for diagnosis of PMN using positive PLA2R and THSD7A were evaluated.

Results: Of the 88 patients included, 41 had PMN with a mean age of 44.5 ± 17.5 years and 61.0% were female. Histologically, PLA2R and THSD7A were only positive in the PMN group (51.2% and 4.9%, respectively) but negative in both control groups. The sensitivity of PLA2R and THSD7A for identifying PMN was 51.2% and 4.9%, respectively. The sensitivity of both tests together was 53.7% while the specificity and positive predictive values (PPV) for any of the tests (alone or in combination) was 100%. There was no difference in the sensitivity and specificity when using PLA2R alone compared to combining the two tests \( (p=0.32) \).

Conclusion: Glomerular staining of PLA2R and THSD7A could have potential diagnostic values in South Africans. This has implications on how immunotherapies can be initiated and used in these settings.

Keywords: Africans, Primary membranous nephropathy, Lupus nephritis, PLA2R, THSD7A

* Correspondence: Ikechi.Okpechi@uct.ac.za
1Division of Nephrology and hypertension, University of Cape Town, Cape Town, South Africa
2Kidney and Hypertension Research Unit, University of Cape Town, Cape Town, South Africa
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Membranous glomerulonephritis (MGN) is a leading cause of the nephrotic syndrome in adults and occurs as a primary disorder (primary membranous nephropathy – PMN) or secondary to other disorders like lupus nephritis, infections and certain drugs.[1–6] Primary membranous nephropathy is a kidney-specific autoimmune disorder in which anti-glomerular basement membrane antibodies develop against self, podocyte antigens.[5] Phospholipase A2 receptor 1 (PLA2R) and thrombospondin type-1 domain containing 7A (THSD7A) are two podocyte specific antigens that have been identified in PMN.[7, 8] Determining the presence or absence of PLA2R and anti-THSD7A antibodies in serum and renal biopsy specimen, has significantly reshaped the diagnostic approach to PMN by providing important immunologic information which aid in discriminating between primary and secondary MGN, as well as predicting clinical outcomes in PMN.[9] Clinically, PLA2R and anti-THSD7A antigens may be identified in sera by immunostaining methods in renal biopsy samples. While quantitative and semi-quantitative serologic assays are now commercially available for PLA2R and THSD7A antibodies, it has been noted that a significant number of individuals with histologically confirmed antigens to PLA2R in glomerular deposits (and hence a biopsy diagnosis of PMN) have negative PLA2R serology results.[10] It has also been shown that early in the time course of PMN, due to delayed seroconversion, PLA2R may be negative in serum but demonstrable in histologic specimen.[11] Kidney biopsy tissue-based testing may thus be a veritable diagnostic tool in appropriately identifying PMN.

The sensitivity and specificity of these tissue-based antibody tests in identifying PMN have largely varied across studies. However, one meta-analysis reported a pooled sensitivity and specificity of 65% (63–67%) and 97% (97–98%) for serum PLA2R antibodies and 79% (76–81%) and 90% (88–92%), respectively, for glomerular PLA2R antigens.[12] Hoxha et al.,[13] in a prospective cohort of 345 patients with MN reported the prevalence of THSD7A-associated MN to be 2.6% with 92% sensitivity and a 100% specificity using immunofluorescence techniques. Given that MGN (both primary and secondary types due to hepatitis B and lupus nephritis) has been shown to be a common cause of nephrotic syndrome in adults in African studies of kidney biopsies, differentiating primary from secondary type is important for making therapeutic decisions.[3, 6, 14] There are currently no studies in Africa assessing the utility of serum or glomerular PLA2R or THSD7A for accurately identifying patients with PMN. The aim of this study is to assess the sensitivity and specificity of PLA2R and THSD7A for identifying PMN in South African patients using kidney biopsy tissue-based antibody tests.

Methods
Study population and study design
The study was approved by the Human Research Ethics Committee of the University of Cape Town (HREC/REF: 662/2017). This was a cross-sectional study of patients with native kidney biopsy proven PMN, collected consecutively over a 10-year period (2007 to 2016). Patients known with lupus nephritis (LN) with biopsy proven secondary membranous LN (LN-V) and patients with diabetes mellitus whose biopsies showed classical features of diabetic nephropathy (DN) were included as controls. All the patients were selected from the renal biopsy registry of the Division of Nephrology and Hypertension, Groote Schuur Hospital (GSH), University of Cape Town. Given the retrospective nature of this study, patient consent was not required for this study.

Data collection
We collected relevant demographic, clinical, serological, biochemical and histological data of all patients. Data recorded were age, gender, race, systolic and diastolic blood pressures (SBP and DBP) and presence of oedema. Serological data collected include full blood count, serum creatinine, estimated glomerular filtration rate (eGFR) using the modification of diets in renal disease (MDRD) equation,[15] urine protein-creatinine ratio (UPCR), serum cholesterol and albumin. Serologies for human immunodeficiency virus (HIV), Hepatitis B, syphilis and anti-nuclear antibodies (ANA) and anti-double stranded deoxyribonucleic acid (anti-dsDNA) were checked in all patients to ensure that common secondary causes of membranous nephropathy were excluded.

Histology
The diagnosis of PMN was based on typical light microscopy and immunohistochemistry (IHC) findings, showing thickening of glomerular basement membrane with or without spikes and granular deposition of immunoglobulin (Ig)G and C3 along the glomerular capillary walls.[16] All patients who had been labelled as PMN had tested negative for HIV, Hepatitis B and C, syphilis and for all immunological markers of lupus. For the histology, we collected data on number of glomeruli in each biopsy, presence of tubular atrophy, interstitial fibrosis and immunoglobulin deposits in IHC stains (IgG, IgA, IgM, C3) as well as the results for PLA2R and THSD7A. All histology results were entered as positive (present) or negative (absent). All slides for PLA2R and THSD7A were stained using standard methods as described by manufacturers and all were analyzed and reviewed by a single pathologist (FCJB). For the IHC staining, we utilized methods previously described in another study.[17] Briefly, 3 µm of formalin fixed paraffin embedded sections of biopsy specimen was
deparaffinized and rehydrated. After endogenous peroxidase blockage and antigen retrieval, slides were incubated with the antibody. For the PLA2R stain, the antibody used was HPA012657-100UL (Sigma Aldrich, rabbit polyclonal antibody, dilution 1:1000) and for THSD7A, it was HPA000923-100UL (Sigma Aldrich, rabbit polyclonal antibody, dilution 1:1000). Multiple washes were performed, and the specimens were washed in phosphate buffered saline (PBS) and developed in 3, 3’-diaminobenzidine (DAB). Quality control evaluation was performed on the stained slides to confirm correct and appropriate staining by comparison with controls. The IHC stained slides were reviewed and assessed using a semi-quantitative method to reveal the intensity and position of staining i.e. by the presence of granular staining in the glomeruli by the nephropathologist.

**Statistical analysis**

Data analysis was performed using Stata 15.1 (StataCorp, TX, USA). Numerical variables were reported as mean (± standard deviation) if normally distributed and as median (interquartile range) if skewed. Analysis of variance (ANOVA), or its non-parametric equivalent (the Kruskall-Wallis test) was used to compare means across groups with pairwise comparisons performed using the Bonferroni correction. The Chi-square test was used to compare proportions. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV), and their 95% confidence intervals, for diagnosis of PMN using positive PLA2R and THSD7A were calculated based on standard methods.[18] A p-value < 0.05 was taken as significant.

**Results**

**Demographic and Clinical Characteristics**

Overall, there were eighty-eight (88) patients included in this study: 41 with PMN, 19 with pure class V lupus nephritis (LN-V) and 28 with diabetic nephropathy (DN). Serologies for HIV, Hepatitis B and syphilis were negative for all study subjects. The mean age at presentation for patients with PMN was 44.5 ± 17.5 years; patients with LN-V were significantly younger (p = 0.02). There was an overall female preponderance, however, there was no significant gender difference observed across groups (p = 0.07). Patients with PMN had a significantly higher serum cholesterol (p = 0.001) and lower serum albumin (p = 0.004) while the eGFR was lowest in the group with DN (P = 0.001). Although the UPCR was much higher in the PMN group, there was no significant difference between groups (p = 0.07). Other clinical and biochemical results are shown in Table 1.

**Histologic Characteristics**

The histological features of included biopsies are summarized in Table 2. There were significant differences in the number of sclerosed glomeruli, presence of tubular atrophy and interstitial fibrosis (all highest in the DN group). PLA2R and THSD7A were only positive in the PMN group (51.2% and 4.9%, respectively) and were negative in the control groups. Only one patient with PMN showed enhanced granular expression of both PLA2R and THSD7A while another PMN patient who was negative for PLA2R was positive for THSD7A. A comparison of the demographic and clinical characteristics of PMN

| Table 1 Demographic and Clinical Characteristics of the study population |
|---------------------------------------------------------------|
| **PMN** (n = 41) | **LN-V** (n = 19) | **DN** (n = 28) | **p-value** | **Total** (n = 88) |
|------------------|------------------|----------------|-------------|------------------|
| Age (years)      | 44.5 ± 17.5      | 33.8 ± 13.9    | 46.8 ± 14.2 | 0.02             | 42.9 ± 16.4 |
| Female gender [n (%)] | 25 (61.0)       | 17 (89.5)     | 18 (64.3)  | 0.07             | 60 (68.2)  |
| Race (Black) [n (%)] | 13 (31.7)      | 7 (36.8)      | 9 (32.1)   | 0.92             | 29 (32.9)  |
| mABP (mmHg)      | 94.6 ± 11.7      | 85.7 ± 8.0     | 99.4 ± 16.1 | 0.01             | 94.3 ± 13.4 |
| Presence of oedema [n (%)] | 26 (69.7)     | 8 (53.3)      | 16 (64.0)  | 0.02             | 50 (72.5)  |
| Hb (g/dL)        | 11.8 ± 2.1       | 10.6 ± 2.3     | 9.9 ± 1.7   | 0.001            | 11.0 ± 2.2  |
| Platelet count (x10^3/L) | 368.4 ± 129.2  | 307.4 ± 149.4 | 340.9 ± 137.1 | 0.34             | 348.3 ± 135.7 |
| WBC count (x10^3/L) | 8.4 ± 2.4       | 8.5 ± 4.6      | 9.0 ± 3.2   | 0.76             | 8.6 ± 3.1   |
| Total cholesterol (mmol/L) | 9.3 (7.8–11.6)  | 4.6 (3.7–5.8) | 6.3 (4.8–7.9) | 0.001            | 7.8 (5.5–9.6) |
| Serum albumin (g/L) | 21.8 ± 7.1      | 25.4 ± 7.4     | 28.0 ± 5.9  | 0.004            | 24.3 ± 7.3  |
| UPCR (g/mmol creatinine) | 0.87 (0.49–1.26) | 0.54 (0.27–0.75) | 0.52 (0.17–1.34) | 0.07 | 0.72 (0.34–1.24) |
| Serum creatinine (µmol/L) | 80 (63–103)   | 72 (51–123)    | 188 (97–471) | 0.001            | 96 (66–167) |
| eGFR (mL/min/1.73 m²) | 85 (57–124)     | 98 (49–137)    | 30 911 – 63 | 0.001            | 68 (38–111) |

PMN Primary membranous nephropathy, LN-V class V lupus nephritis, DN diabetic nephropathy, mABP Mean Arterial Blood Pressure, Hb Haemoglobin, WBC White Blood Cell, UPCR Urine Protein Creatinine Ratio, eGFR estimated glomerular filtration rate

The 24-hour value of proteinuria (g/24Hrs) is approximately 10-times the ratio of the UPCR in g/mmol creatinine
Table 2  Histologic Characteristics of biopsies included in this study

|                         | PMN  (n = 41) | LN-V (n = 19) | DN  (n = 28) | p-value | Total |
|-------------------------|--------------|--------------|-------------|---------|-------|
| Number of glomeruli per view (n [IQR])  | 15 (10–21)  | 16 (8–20)  | 16 (10–26) | 0.47    | 15 (10–23) |
| Sclerosed glomeruli (n)  | 0.0 (0.0-6.7) | 0.0 (0.0-2.6) | 22.5 (8.4–48.7) | 0.001 | 0.0 (0.0-14.8) |
| Tubular atrophy [n (%)] | 7 (17.1) | 4 (21.1) | 18 (64.3) | < 0.001 | 29 (32.9) |
| Interstitial fibrosis [n (%)] | 12 (29.3) | 7 (36.8) | 26 (92.9) | < 0.001 | 45 (51.1) |

Immunochemistry:
- IgG [n (%)] 31 (75.6) 16 (84.2) 4 (14.3) < 0.001 51 (57.9)
- IgA [n (%)] 9 (21.9) 7 (36.8) 1 (3.6) 0.02 17 (19.3)
- IgM [n (%)] 16 (39.0) 13 (68.4) 8 (28.6) 0.02 37 (42.1)
- C3 [n (%)] 31 (75.6) 10 (52.6) 7 (25.0) < 0.001 48 (54.5)
- PLA2R (positive) 21 (51.2) 0 (0.0) 0 (0.0) < 0.001 21 (23.9)
- THSD7A (positive) 2 (4.9) 0 (0.0) 0 (0.0) 0.31 2 (2.3)

PMN Primary membranous nephropathy, LN-V class V lupus nephritis, DN diabetic nephropathy, IQR Interquartile range; IgA Immunoglobulin A, IgG Immunoglobulin G, IgM Immunoglobulin G, C3 Complement factor 3; PLA2R phospholipase A-2 receptor; THSD7A thrombospondin type-1 domain containing 7A

Table 3  Characteristics of Patients with positive expression of PLA2R in the glomeruli

|                         | PMN (PLA2R positive) (n = 21) | PMN (PLA2R negative) (n = 20) | p-value |
|-------------------------|-------------------------------|-------------------------------|---------|
| Age (years)             | 44.71 ± 14.93                 | 43.90 ± 20.46                 | 0.88    |
| Female gender [n (%)]   | 11 (52.38)                    | 14 (70.00)                    | 0.25    |
| Race (Black) [n (%)]    | 7 (33.33)                     | 14 (66.67)                    | 0.82    |
| mABP (mmHg)             | 93.7 ± 10.8                   | 95.48 ± 12.91                 | 0.65    |
| Presence of oedema (%)  | 12 (57.1)                     | 14 (70.0)                     | 0.39    |
| Hb (g/dl)               | 12.1 ± 1.9                    | 11.5 ± 2.2                    | 0.35    |
| Platelet count (x10^9/L)| 363.3 ± 147.5                 | 374.7 ± 106.4                 | 0.79    |
| WBC count (x10^9/L)     | 7.8 ± 2.0                     | 9.2 ± 2.7                     | 0.06    |
| Total cholesterol (mmol/L) | 10.6 ± 4.2                 | 8.9 ± 3.5                     | 0.25    |
| Serum albumin (g/L)     | 22.8 ± 6.3                    | 20.5 ± 7.9                    | 0.34    |
| UPCR (g/mmol creatinine)| 0.9 (0.7–1.1)                 | 0.8 (0.4–1.3)                 | 0.65    |
| Serum creatinine (µmol/L)| 88.0 (64.0–106.0)          | 77.5 (61.0–101.0)             | 0.50    |
| eGFR (mL/min/1.73 m²)   | 85.0 (54.0–111.0)             | 85.5 (60.0–131.5)             | 0.57    |
| Tubular atrophy [n (%)] | 5 (23.8)                      | 2 (10.0)                      | 0.24    |
| Interstitial fibrosis [n (%)] | 5 (23.8)                  | 7 (35.0)                      | 0.43    |
| IgG positive [n (%)]    | 18 (85.7)                     | 13 (65.0)                     | 0.12    |
| IgA positive [n (%)]    | 5 (23.8)                      | 4 (20.0)                      | 0.77    |
| IgM positive [n (%)]    | 11 (52.4)                     | 5 (25.0)                      | 0.07    |
| C3 positive [n (%)]     | 17 (80.9)                     | 14 (70.0)                     | 0.41    |

mABP Mean Arterial Blood Pressure; Hb Haemoglobin; WBC White Blood Cell; UPCR Urine Protein Creatinine Ratio; eGFR estimated glomerular filtration rate; IgA Immunoglobulin A; IgG Immunoglobulin G; IgM Immunoglobulin G; C3 Complement factor 3; PLA2R phospholipase A-2 receptor

The 24-hour value of proteinuria (g/24Hrs) is approximately 10-times the ratio of the UPCR in g/mmol creatinine
patients with positive and negative expression of PLA2R in their biopsies is shown in Table 3. There were no identified demographic or clinical differences between both groups.

Comparison of PLA2R positive PMN and class V LN
Table 4 shows the clinical and histological features of patients with positive PLA2R and LN-V group. Both serum cholesterol ($p = 0.002$) and UPCR ($p = 0.04$) were significantly higher in the positive PLA2R group. There were no significant differences in the histological features between both groups.

Sensitivity and Specificity of PLA2R and THSD 7A for idiopathic membranous nephropathy
Table 5 provides a summary of the sensitivity, specificity, positive and negative predictive values of enhanced expression of PLA2R and THSD7A (alone and in combination) for predicting PMN. PLA2R and THSD7A (alone or when combined) showed a specificity and positive predictive values (PPV) of 100%. The sensitivity (alone or combined) of PLA2R and THSD7A were 51.2% [95%CI 35.1% – 67.1%], 4.9% [95%CI 0.6% – 16.5%] and 53.7% [95%CI 37.4% – 69.3%] respectively. There was no difference in the sensitivity and specificity when using PLA2R alone compared to combining the two tests ($p = 0.32$) (analysis not shown).

Table 4 Characteristics of Patients with positive expression of PLA2R and LN-V

|                     | PMN (PLA2R positive) | LN-V (n = 19) | p   |
|---------------------|----------------------|---------------|-----|
| Age (years)         | 44.71                | 33.8 ± 13.9   | 0.02|
| Female gender [n (%)]| 11 (52.4)            | 17 (89.5)     | 0.01|
| Race (Black) [n, %] | 7 (33.3)             | 7 (36.8)      | 0.82|
| mABP (mmHg)         | 93.7 ± 10.8          | 85.7 ± 8.0    | 0.03|
| Presence of oedema [n (%)] | 12 (57.14)         | 8 (42.11)     | 0.34|
| Hb (g/dL)           | 12.1 ± 1.9           | 10.6 ± 2.3    | 0.03|
| Platelet count (x10^9/L) | 363.3 ± 147.5        | 307.4 ± 149.5 | 0.28|
| WBC count (x10^9/L) | 7.8 ± 2.0            | 8.5 ± 4.6     | 0.53|
| Total cholesterol (mmol/L) | 9.9 (8.7–11.8)     | 4.6 (3.7–5.8) | 0.002|
| Serum albumin (g/L) | 22.8 ± 6.28          | 25.45 ± 7.35  | 0.30|
| UPCR (g/mmol creatinine) | 0.9 (0.7–1.1)       | 0.54 (0.3–0.8)| 0.04|
| Serum creatinine (µmol/L) | 88.0 (64.0–106.0)   | 72.0 (51.0–123.0)| 0.65|
| eGFR (ml/min/1.73 m^2) | 85.0 (54.0–111.0)   | 98.0 (49.0–137.0)| 0.74|
| Number of glomeruli per view (n) | 14 (10–20)          | 16 (8–20)    | 0.97|
| Tubular atrophy [n (%)] | 5 (23.8)           | 4 (21.1)      | 0.83|
| Interstitial fibrosis [n (%)] | 5 (23.8)           | 7 (36.8)      | 0.37|

Immunohistochemistry:
- IgG [n (%)] | 18 (85.7) | 16 (84.2) | 0.89
- IgA [n (%)] | 5 (23.8)  | 7 (36.8)  | 0.37
- IgM [n (%)] | 11 (52.4) | 13 (68.4) | 0.30
- C3 [n (%)]  | 17 (80.9) | 10 (52.6) | 0.06

mABP Mean Arterial Blood Pressure; Hb Haemoglobin; WBC White Blood Cell; UPCR Urine Protein Creatinine Ratio; eGFR estimated glomerular filtration rate; IgA Immunoglobulin A; IgG Immunoglobulin G; IgM Immunoglobulin M; C3 Complement factor 3; PLA2R phospholipase A-2 receptor
The 24-hour value of proteinuria (g/24Hrs) is approximately 10-times the ratio of the UPCR in g/mmol creatinine

Table 5 Sensitivity, specificity, PPV and NPV of PLA2R and THSD7A

|                | Sensitivity | Specificity | PPV  | NPV  |
|----------------|-------------|-------------|------|------|
| PLA2R          | 51.2 (35.1–67.1) | 100 (92.5–100) | 100 (83.9–100) | 96.7 (95.5–97.5) |
| THSD7A         | 4.9 (0.6–16.5)  | 100 (92.5–100) | 100 (93.3–94.1) | 93.7 (93.3–94.1) |
| PLA2R & THSD7A | 53.7 (37.4–69.3) | 100 (92.5–100) | 100 (84.6–100) | 71.2 (58.7–81.7) |

All values are presented as percentage and (95% confidence interval); PPV positive predictive value; NPV Negative predictive value; PLA2R phospholipase A-2 receptor; THSD7A thrombospondin type-1 domain containing 7A
**Discussion**

With the identification of candidate podocyte antigen targets such as PLA2R and THSD7A and their respective PLA2R and anti-THSD7A autoantibodies, the autoimmune basis of MGN has effectively been established. Our study aimed to determine the occurrence of novel antigens associated with MGN among South African patients previously defined as PMN by standard microscopic techniques. We found a respective frequency of occurrence of positive glomerular staining for PLA2R and THSD7A in 51.2% (21/41 patients) and 4.9% (2/41 patients) of biopsies initially categorized as PMN. None of the biopsies of LN-related MGN or DN stained positively for either PLA2R or THSD7A.

Since the canonical work of Beck et al. [7] in which the autoimmune target podocyte antigen PLA2R was discovered, the prevalence of PLA2R antibody in serum and/or PLA2R antigen in kidney tissue deposits in PMN have been variously described among different populations. In our cohort of predominantly non-black South Africans, the frequency of occurrence of histologic autoantibody positivity was relatively low at 51.2% compared to data from European cohorts in whom rates from 69.2–73.8% have been observed.[10, 19] Among Japanese patients however, lower rates as seen in our study have also been reported.[20] Evidence continues to accrue for a genetic component in the pathogenesis of PMN and a genetic role in the varying prevalence observed particularly with respect to PLA2R autoantibody positivity across different ethnicities. *HLA-DQA1* and *PLA2R1* are risk alleles for PMN that have been identified and demonstrated to confer different disease risk in different populations with a strong association shown among European, Indian, Chinese but not African Americans patients.[21–23].

Approximately 1 in 2 patient histologic samples initially identified as PMN by standard microscopic techniques did not demonstrate enhanced glomerular immune deposits staining for PLA2R antigen. This PLA2R immune deposit negative state could be accounted for by either of two possibilities. It is probable that these are indeed PMN cases with yet to be identified target podocyte antigen(s) as research continues to identify other candidate glomerular antigens that are autoimmune targets in PMN. Indeed 1 of our 20 PLA2R negative patients had a positive glomerular immune deposit staining for THSD7A, an antigenic target that was identified 6 years after PLA2R. Other novel proteins including neural epidermal growth factor-like 1 protein (NELL-1) [24] and Semaphorin 3B [25] have recently been identified to be associated with membranous nephropathy. NELL-1 was present in 23% [29/126] of European PLA2R and THSD7A negative PMN patients while Semaphorin 3B was predominantly present in paediatric patients with MGN.[24, 25].

These discoveries lend credence to our hypothesis that other glomerular basement membrane antigens may well underly the pathogenesis of PMN in this African cohort, especially with our relatively younger group of patients. An alternate explanation could be that these are secondary cases of MGN currently misidentified as PMN as predisposing factors such as in chronic viral infections like chronic hepatitis B, autoimmune disorders such as LN and solid organ malignancies were not clinically apparent and detectable by routine checks at the time of renal biopsy. Hepatitis-B associated glomerular disease and LN constitute the two commonest causes of secondary GNs in Africa and in both entities glomerular disease has been known to occur in the absence of systemic evidence of chronic hepatitis B antigenemia and lupus serologies respectively.[3, 26] We however could not demonstrate any significant clinical or histologic differences between our PLA2R positive and PLA2R negative patients to suggest that they represent two distinct pathogenetic groups of patients (Table 3). Unfortunately, we were unable to stain the biopsies for exostosin which can detect cases labelled as PMN but related to LN. Sethi et al.[27] detected exostosin 1 (EXT1) and exostosin 2 (EXT2) in 21 cases of PLA2R-negative MN, but not in PLA2R-associated MN and control cases, suggesting that subset of MN is associated with accumulation of EXT1 and EXT2 in the GBM. Thus, a yet to be identified glomerular antigen in this African group of PMN patient may be a more probable theory underlying PLA2R negative immune deposit staining. It is also possible, although we used an IHC method that has been previously described, that methodological differences in IHC techniques could have contributed to the proportion of PLA2R positive biopsies in our group.

Distinguishing between PMN and LN-V histologically has traditionally rested upon the additional demonstration of subendothelial deposits, mesangial hypercellularity and positive IHC/IF staining for C3, C1q, IgM, IgA and IgG1/IgG3 subclass in LN-V biopsies. Positive staining for glomerular PLA2R antigen by IF/IHC has now been added to the armamentarium of diagnostic tools in differentiating between PMN and LN-V with the latter typically, but not always, demonstrating negative serum PLA2R antibodies and/or glomerular staining for the PLA2R antigen.[28] Although we were not able to subtype IgG class or stain for C1q, we could not broadly exemplify this differential IHC staining pattern between our PMN patients and LN-V patients (Table 4). Although immunofluorescence examination can aid in differentiating LN-V from PMN given the absence of IgM, IgA, and C1q in the latter, it has been noted that these differences can be challenging due to the overlap that can occur.[20, 29] This may explain the presence, in
a few PMN patients, of positive IgA, IgM and C1q despite these patients testing negative for all common secondary causes of MGN. Based on our findings there were notable clinical differences between PLA2R positive patients and LN-V patients with PLA2R patients having 1.7 fold heavier proteinuria and more than 2-fold higher total serum cholesterol levels than lupus MN patients; as is typical for the demographic epidemiology of lupus, there was a female predisposition for lupus. Dual positivity for the glomerular PLA2R and THSD7A antigens in patients with PMN is being increasingly reported from some studies.[30, 31] Only one patient in our cohort demonstrating dual positivity was demonstrated. It remains unclear the clinical implications of this dual staining pattern. Our study is not without its limitations. Firstly, we were unable to stain the PLA2R negative samples for EXT1 and EXT 2, especially considering the younger age of patients in our study. This may have shown, as others have done in recent studies,[27] that some PLA2R negative patients treated as PMN could be patients with LN. Additionally, there was no outcome data reported for the patients to evaluate the role of glomerular PLA2R or THSD7A reactivity with response to therapy and disease progression. Our study was not designed to do this as we wanted to assess the relevance of these tests in an African population given that there are no previous studies. Furthermore, we were also unable to include the biopsies of patients with cancers and secondary MN to assess if THSD7A shows any association in such patients in our population. Lastly, we did not have serum samples at the time of diagnosis of MGN to assess serum PLA2R antibodies and determine if there existed any correlation between serum PLA2R antibodies and glomerular staining in our PLA2R positive patients. Despite these limitations and given the high specificity and PPV of our study results, it shows that glomerular PLA2R and THSD7A staining can be used for identifying PMN in African patients with MGN. We also encourage outcome studies using these tests in patients with biopsy proven PMN as this will improve the use of appropriate therapies for treating patients.

Conclusions
This study shows that glomerular staining of PLA2R and THSD7A can be used to identify patients with PMN in South African patients with biopsy proven MGN. This means that immunotherapies for such patients can be appropriately initiated and judiciously monitored. Our study also showed that a combination of PLA2R and THSD7A may not provide better diagnostic accuracy compared to PLA2R only and that PMN patients with positive glomerular staining for PLA2R tend to have a more severe form nephrotic syndrome evidenced by higher UPCR compared with PLA2R-negative patients. There is need for further studies in other African populations to assess if glomerular and/or serum PLA2R and THSD7A can be used for identifying patients with PMN.

Acknowledgements
None.

Authors’ contributions
BFL and IGO conceived the study, BFL, OIA, UEE and FCJB were involved in data collection, BFL, OIA, UEE and IGO were involved in data analysis and writing up of the manuscript; BFL, OIA, UEE, FCJB, USO, NW, PR, AKB and IGO were involved in interpretation and revision of the manuscript for intellectual content. All authors approved the final version of the manuscript.

Funding
This research was supported by incentive funding for rated researchers from the National Research Foundation (NRF - IFR180213312495). The funder had no role in design of the study and collection, analysis, and interpretation of data or in writing the manuscript.

Availability of data and materials
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Ethics approval was obtained from the University of Cape Town Human Research Ethics Committee (HREC/REF: 662/2017). Given the retrospective nature of this study, patient consent was not required for this study.

Consent for publication
Not Applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Division of Nephrology and hypertension, University of Cape Town, Cape Town, South Africa. 2Kidney and Hypertension Research Unit, University of Cape Town, Cape Town, South Africa. 3Mount Meru Regional Referral Hospital, Arusha, Tanzania. 4Division of Nephrology, Zenith Medical & Kidney Centre, Gudu, Abuja, Nigeria. 5Department of Medicine, University of Uyo, Uyo, Nigeria. 6Pathcare Laboratories, George, South Africa. 7Division of Anatomical pathology, University of Cape Town, Cape Town, South Africa. 8Department of Internal Medicine, Federal Medical Centre, Jabi, Abuja, Nigeria. 9Department of Nephrology and Dialysis, Assistance Publique-Hôpitaux de Paris, Tenon Hospital, Paris, France. 10Department of Medicine, University of Alberta, Edmonton, Canada.

Received: 22 July 2020 Accepted: 20 December 2020

Published online: 07 January 2021

References
1. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414–30.
2. Woo KT, Chain CM, Lim C, Choo J, Chin YM, Teng EWL, Mok I, Kwek JL, Loh AH-L, Choong HL, et al. A Global Evolutionary Trend of the Frequency of Primary Glomerulonephritis over the Past Four Decades. Kidney diseases (Basel Switzerland). 2019;5(4):247–58.
3. Okpechi IG, Ameh IO, Bello AK, Ronco P, Swanepoel CR, Kengne AP. Epidemiology of Histologically Proven Glomerulonephritis in Africa: A Systematic Review and Meta-Analysis. PloS One. 2016;11(3):e0152203.
4. O'Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC. Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. Nephrol Dial Transplant 2017.
5. Couser WG. Primary Membranous Nephropathy. Clinical journal of the American Society of Nephrology. CJASN. 2017;12(6):983–97.
6. Vermeulen A, Menezes CN, Mashabane M, Butler OK, Mosiane P, Goetsch S, Naicker S. Patterns of renal disease: A 30-year renal biopsy study at Chris Hani Baragwanath Academic Hospital, Soweto, Johannesburg, South Africa. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 2019; 109(7):486–492.

7. Beck LH Jr, Bonego RC, Lambeau G, Beck DM, Powell DW, Cummings TD, Klein JB, Salant DJ. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21.

8. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Zahnner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, et al. Thrombospondin type 1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277–87.

9. Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 2017;13(9):563–79.

10. Svobodova B, Honova E, Ronco P, Tesar V, Debiec H. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant. 2013;28(7):1839–44.

11. van de Logt AE, Hofstra JM, Wetzels JF. Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up. Kidney Int. 2015;88(6):1263–4.

12. Li W, Zhao Y, Fu P. Diagnostic Test Accuracy of Serum Anti-PLA2R Autoantibodies and Glomerular PLA2R Antigen for Diagnosing Idiopathic Membranous Nephropathy: An Updated Meta-Analysis. Front Med (Lausanne). 2018;5:101.

13. Ohashi N, Kato A, Baba S, Yasuda H. Prevalence of Enhanced factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2019;95(2):268–75.

14. L’Impero V, Pienzufi T, Sinco RA, Nebuloni M, Granata A, Smith A, Radice A, Pagni F. Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 domain-containing 7A in primary membranous nephropathy. J Pathol. 2018;245(1):65–73.

15. Raggi MA, Markert RJ, Stutes SA. Selecting and interpreting diagnostic tests. Biochemia medica: Biochemia medica. 2007;17(2):151–61.

16. Hoxha E, Beck LH Jr, Wich T, Tomas NM, Probst C, Mholdorff S, Meyer-Schwesinger C, Zahnner G, Stahl PR, Schomper R, et al. An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy. Journal of the American Society of Nephrology: JASN. 2017; 28(2):520–31.

17. Borsoum RS, Francis MR. Spectrum of glomerulonephritis in Egypt. Saudi journal of kidney diseases transplantation: an official publication of the Saudi Center for Organ Transplantation Saudi Arabia. 2000;11(3):421–9.

18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.

19. Borsoum RS, Francis MR. Spectrum of glomerulonephritis in Egypt. Saudi journal of kidney diseases transplantation: an official publication of the Saudi Center for Organ Transplantation Saudi Arabia. 2000;11(3):421–9.

20. Li W, Zhao Y, Fu P. Diagnostic Test Accuracy of Serum Anti-PLA2R Autoantibodies and Glomerular PLA2R Antigen for Diagnosing Idiopathic Membranous Nephropathy: An Updated Meta-Analysis. Front Med (Lausanne). 2018;5:101.

21. L’Impero V, Pienzufi T, Sinco RA, Nebuloni M, Granata A, Smith A, Radice A, Pagni F. Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 domain-containing 7A in primary membranous nephropathy. J Pathol. 2018;245(1):65–73.

22. Raggi MA, Markert RJ, Stutes SA. Selecting and interpreting diagnostic tests. Biochemia medica: Biochemia medica. 2007;17(2):151–61.

23. Hoxha E, Kneißler U, Stege G, Zahner G, Thiele I, Panzer U, Harendza S, Helmchen UM, Stahl RA. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 2012;82(7):797–804.

24. Iwakura Y, Ohashi N, Kato A, Baba S, Yasuda H. Prevalence of Enhanced Granular Expression of Thrombospondin Type-1 Domain-Containing 7A in the Glomeruli of Japanese Patients with Idiopathic Membranous Nephropathy. PLoS One. 2015;10(9):e0138841.

25. Li W, Zhao Y, Fu P. Diagnostic Test Accuracy of Serum Anti-PLA2R Autoantibodies and Glomerular PLA2R Antigen for Diagnosing Idiopathic Membranous Nephropathy: An Updated Meta-Analysis. Front Med (Lausanne). 2018;5:101.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.